333 related articles for article (PubMed ID: 27049722)
1. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.
Siaw JT; Wan H; Pfeifer K; Rivera VM; Guan J; Palmer RH; Hallberg B
Oncotarget; 2016 May; 7(20):29011-22. PubMed ID: 27049722
[TBL] [Abstract][Full Text] [Related]
2. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Huang WS; Liu S; Zou D; Thomas M; Wang Y; Zhou T; Romero J; Kohlmann A; Li F; Qi J; Cai L; Dwight TA; Xu Y; Xu R; Dodd R; Toms A; Parillon L; Lu X; Anjum R; Zhang S; Wang F; Keats J; Wardwell SD; Ning Y; Xu Q; Moran LE; Mohemmad QK; Jang HG; Clackson T; Narasimhan NI; Rivera VM; Zhu X; Dalgarno D; Shakespeare WC
J Med Chem; 2016 May; 59(10):4948-64. PubMed ID: 27144831
[TBL] [Abstract][Full Text] [Related]
4. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
5. Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells.
Alam MW; Borenäs M; Lind DE; Cervantes-Madrid D; Umapathy G; Palmer RH; Hallberg B
Front Oncol; 2019; 9():579. PubMed ID: 31334113
[TBL] [Abstract][Full Text] [Related]
6. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
7. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
8. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.
Passaro A; Prelaj A; Pochesci A; Spitaleri G; Rossi G; Del Signore E; Catania C; de Marinis F
Drugs Today (Barc); 2017 Aug; 53(8):435-446. PubMed ID: 29119148
[TBL] [Abstract][Full Text] [Related]
9. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
10. Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on Inhibition of ER-phagy.
Zhang Z; Gao W; Zhou L; Chen Y; Qin S; Zhang L; Liu J; He Y; Lei Y; Chen HN; Han J; Zhou ZG; Nice EC; Li C; Huang C; Wei X
Theranostics; 2019; 9(17):4878-4892. PubMed ID: 31410188
[No Abstract] [Full Text] [Related]
11. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.
Schönherr C; Ruuth K; Yamazaki Y; Eriksson T; Christensen J; Palmer RH; Hallberg B
Biochem J; 2011 Dec; 440(3):405-13. PubMed ID: 21838707
[TBL] [Abstract][Full Text] [Related]
12. Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.
Ceccon M; Mologni L; Giudici G; Piazza R; Pirola A; Fontana D; Gambacorti-Passerini C
Mol Cancer Res; 2015 Apr; 13(4):775-83. PubMed ID: 25421750
[TBL] [Abstract][Full Text] [Related]
13. The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
Guan J; Tucker ER; Wan H; Chand D; Danielson LS; Ruuth K; El Wakil A; Witek B; Jamin Y; Umapathy G; Robinson SP; Johnson TW; Smeal T; Martinsson T; Chesler L; Palmer RH; Hallberg B
Dis Model Mech; 2016 Sep; 9(9):941-52. PubMed ID: 27483357
[TBL] [Abstract][Full Text] [Related]
14. Dual
Wood AC; Krytska K; Ryles HT; Infarinato NR; Sano R; Hansel TD; Hart LS; King FJ; Smith TR; Ainscow E; Grandinetti KB; Tuntland T; Kim S; Caponigro G; He YQ; Krupa S; Li N; Harris JL; Mossé YP
Clin Cancer Res; 2017 Jun; 23(11):2856-2868. PubMed ID: 27986745
[No Abstract] [Full Text] [Related]
15. Brigatinib for
Ali R; Arshad J; Palacio S; Mudad R
Drug Des Devel Ther; 2019; 13():569-580. PubMed ID: 30804663
[TBL] [Abstract][Full Text] [Related]
16. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.
Redaelli S; Ceccon M; Antolini L; Rigolio R; Pirola A; Peronaci M; Gambacorti-Passerini C; Mologni L
Oncotarget; 2016 Nov; 7(45):72886-72897. PubMed ID: 27662658
[TBL] [Abstract][Full Text] [Related]
17. Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
Okubo J; Takita J; Chen Y; Oki K; Nishimura R; Kato M; Sanada M; Hiwatari M; Hayashi Y; Igarashi T; Ogawa S
Oncogene; 2012 Nov; 31(44):4667-76. PubMed ID: 22249260
[TBL] [Abstract][Full Text] [Related]
18. Brigatinib: First Global Approval.
Markham A
Drugs; 2017 Jul; 77(10):1131-1135. PubMed ID: 28597393
[TBL] [Abstract][Full Text] [Related]
19. Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer.
Spencer SA; Riley AC; Matthew A; Di Pasqua AJ
Ann Pharmacother; 2019 Jun; 53(6):621-626. PubMed ID: 30638036
[TBL] [Abstract][Full Text] [Related]
20. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.
Chand D; Yamazaki Y; Ruuth K; Schönherr C; Martinsson T; Kogner P; Attiyeh EF; Maris J; Morozova O; Marra MA; Ohira M; Nakagawara A; Sandström PE; Palmer RH; Hallberg B
Dis Model Mech; 2013 Mar; 6(2):373-82. PubMed ID: 23104988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]